AstraZeneca PLC (AZNN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AstraZeneca PLC (AZNN) has a cash flow conversion efficiency ratio of 0.048x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (MX$2.34 Billion ≈ $134.78 Million USD) by net assets (MX$48.72 Billion ≈ $2.80 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of AstraZeneca PLC for the company's overall valuation and market capitalisation.
AstraZeneca PLC - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how AstraZeneca PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AstraZeneca PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AstraZeneca PLC ranked by their cash flow conversion efficiency. Explore AZNN operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Morgan Stanley
SA:MSBR34
|
-0.030x |
|
Philip Morris International Inc
NYSE:PM
|
-0.825x |
|
Arm Holdings plc American Depositary Shares
NASDAQ:ARM
|
0.105x |
|
Palo Alto Networks Inc
NASDAQ:PANW
|
0.031x |
|
General Electric Company
SA:GEOO34
|
0.179x |
|
Royal Bank of Canada
TO:RY
|
0.026x |
|
AstraZeneca PLC
NASDAQ:AZN
|
0.071x |
|
Novartis AG ADR
NYSE:NVS
|
0.140x |
Annual Cash Flow Conversion Efficiency for AstraZeneca PLC (2014–2025)
The table below shows the annual cash flow conversion efficiency of AstraZeneca PLC from 2014 to 2025. View AstraZeneca PLC stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | MX$48.72 Billion ≈ $2.80 Billion |
MX$14.57 Billion ≈ $838.80 Million |
0.299x | +3.09% |
| 2024-12-31 | MX$40.87 Billion ≈ $2.35 Billion |
MX$11.86 Billion ≈ $682.60 Million |
0.290x | +9.68% |
| 2023-12-31 | MX$39.17 Billion ≈ $2.25 Billion |
MX$10.36 Billion ≈ $596.39 Million |
0.265x | -0.03% |
| 2022-12-31 | MX$37.06 Billion ≈ $2.13 Billion |
MX$9.81 Billion ≈ $564.45 Million |
0.265x | +74.37% |
| 2021-12-31 | MX$39.29 Billion ≈ $2.26 Billion |
MX$5.96 Billion ≈ $343.17 Million |
0.152x | -50.54% |
| 2020-12-31 | MX$15.64 Billion ≈ $899.97 Million |
MX$4.80 Billion ≈ $276.18 Million |
0.307x | +50.87% |
| 2019-12-31 | MX$14.60 Billion ≈ $840.00 Million |
MX$2.97 Billion ≈ $170.87 Million |
0.203x | +9.12% |
| 2018-12-31 | MX$14.04 Billion ≈ $808.24 Million |
MX$2.62 Billion ≈ $150.67 Million |
0.186x | -13.30% |
| 2017-12-31 | MX$16.64 Billion ≈ $957.75 Million |
MX$3.58 Billion ≈ $205.91 Million |
0.215x | -13.54% |
| 2016-12-31 | MX$16.67 Billion ≈ $959.31 Million |
MX$4.14 Billion ≈ $238.55 Million |
0.249x | +38.46% |
| 2015-12-31 | MX$18.51 Billion ≈ $1.07 Billion |
MX$3.32 Billion ≈ $191.30 Million |
0.180x | -50.01% |
| 2014-12-31 | MX$19.65 Billion ≈ $1.13 Billion |
MX$7.06 Billion ≈ $406.19 Million |
0.359x | -- |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo,… Read more